Anika Therapeutics (ANIK) Cash from Operations Growth (1y) (2011 - 2026)
Anika Therapeutics (ANIK) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn | -261.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -261.90% |
| Mar 31, 2026 | -3,627.69% |
| Dec 31, 2025 | 193.11% |
| Sep 30, 2025 | 36.96% |
| Jun 30, 2025 | 82.32% |
| Mar 31, 2025 | -3.17% |
| Dec 31, 2024 | -56.51% |
| Sep 30, 2024 | -22.65% |
| Jun 30, 2024 | 87.11% |
| Mar 31, 2024 | 96.52% |
| Dec 31, 2023 | 656.34% |
| Sep 30, 2023 | 139.39% |
| Jun 30, 2023 | -368.56% |
| Mar 31, 2023 | -93.58% |
| Dec 31, 2022 | -89.24% |
| Sep 30, 2022 | 31.38% |
| Jun 30, 2022 | -28.09% |
| Mar 31, 2022 | 23.12% |
| Dec 31, 2021 | 72.86% |
| Sep 30, 2021 | -64.84% |